Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action.

MLA

Elmetwalli, Alaa, et al. “Diarylheptanoids/Sorafenib as a Potential Anticancer Combination against Hepatocellular Carcinoma: The P53/MMP9 Axis of Action.” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 396, no. 10, Oct. 2023, pp. 2501–17. EBSCOhost, https://doi.org/10.1007/s00210-023-02470-0.

APA

Elmetwalli, A., Diab, T., Albalawi, A. N., El-Naggar, S. A., El-Far, A. H., Ghedan, A. R., Alamri, E. S., & Salama, A. F. (2023). Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action. Naunyn-Schmiedeberg’s Archives of Pharmacology, 396(10), 2501–2517. https://doi.org/10.1007/s00210-023-02470-0

Chicago

Elmetwalli, Alaa, Thoria Diab, Aisha Nawaf Albalawi, Sabry Ali El-Naggar, Ali H El-Far, Amira Radwan Ghedan, Eman Saad Alamri, and Afrah Fatthi Salama. 2023. “Diarylheptanoids/Sorafenib as a Potential Anticancer Combination against Hepatocellular Carcinoma: The P53/MMP9 Axis of Action.” Naunyn-Schmiedeberg’s Archives of Pharmacology 396 (10): 2501–17. doi:10.1007/s00210-023-02470-0.